Health Minister Nadda Unveils 10th Edition of Indian Pharmacopoeia

Union Health Minister J P Nadda on Friday released the 10th edition of the Indian Pharmacopoeia, the country’s official compendium of drug standards.

Speaking at the launch at the Dr Ambedkar International Centre, Nadda said the Indian Pharmacopoeia 2026 reflects scientific advancements, global best practices and India’s growing leadership in pharmaceutical manufacturing and regulation. He added that the compendium has gained international acceptance and is now recognised in 19 countries across the Global South.

The minister said the latest edition includes 121 new monographs, taking the total number to 3,340. He noted that coverage has been significantly expanded across key therapeutic areas, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, ensuring better standardisation of medicines used under various national health programmes.

“In recent years, Indian Pharmacopoeia standards have gained international acceptance and have become a focused agenda under the health diplomacy of the Government of India,” Nadda said.

Highlighting the progress of the Pharmacovigilance Programme of India under the Indian Pharmacopoeia Commission, Nadda said India has made a sharp global rise. He noted that the country, which ranked 123rd worldwide in contributions to the World Health Organization’s pharmacovigilance database during 2009–2014, has climbed to eighth position in 2025.

Commending the Indian Pharmacopoeia Commission and the PvPI team, the minister said the strengthened pharmacovigilance ecosystem reflects India’s continued commitment to patient safety, quality assurance and strong regulatory oversight.

Nadda also underscored the first-time inclusion of 20 blood component monographs related to transfusion medicine, in line with the Drugs and Cosmetics Rules, 2020.

He said the Indian Pharmacopoeia 2026 underscores the government’s sustained focus on quality, transparency and public welfare.